Qiagen Starts Marketing Own Diagnostic Agents In Japan
This article was originally published in PharmAsia News
Executive Summary
German diagnostics maker Qiagen started marketing three diagnostic agents and two samplers in Japan. The three diagnostics agents use proprietary Hybrid Capture for human papillomavirus, chlamydia and gonococci DNA tests; the company also launched samplers for HPV and other sexually transmitted diseases. Previously, Qiagen products were marketed through Tokyo-based Mitsubishi Chemical Medicine. Qiagen Japanese subsidiary last year obtained the marketing approval and it is now co-promoting HPV products with Mitsubishi. Qiagen Japan has less than 20 sales representatives and the company plans to increase that number as its own marketing operations takes off. (Click here for more - Japanese language
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.